470484-70-9

Basic information

• Product Name: 6-BROMO-1-CHLOROPHTHALAZINE
• Synonyms: 6-BROMO-1-CHLOROPHTHALAZINE;6-BroMo-1-chloro-phthalaz...;PHTHALAZINE, 6-BROMO-1-CHLORO
• CAS NO: 470484-70-9
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.5
• Mol File: 470484-70-9.mol

Chemical Properties

• Boiling Point: 419.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.762±0.06 g/cm3(Predicted)
• PKA: 0.78±0.30(Predicted)
• CAS DataBase Reference: 6-BROMO-1-CHLOROPHTHALAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1-CHLOROPHTHALAZINE(470484-70-9)
• EPA Substance Registry System: 6-BROMO-1-CHLOROPHTHALAZINE(470484-70-9)

Safety Data

• Hazardous Substances Data: 470484-70-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Bromo-1-chlorophthalazine is used as a chemical intermediate for the synthesis of biologically active compounds, contributing to the advancement of pharmaceutical research and development. Its unique properties allow it to be a key component in creating new and effective medications.
Used in Anti-inflammatory Medications:
In the field of anti-inflammatory drugs, 6-Bromo-1-chlorophthalazine is used as a building block for the development of new medications. Its potential to alleviate inflammation makes it a valuable asset in the creation of treatments for various inflammatory conditions.
Used in Antihypertensive Medications:
6-Bromo-1-chlorophthalazine also plays a role in the synthesis of antihypertensive medications, where it is used as a precursor to develop drugs that help lower blood pressure. Its contribution to the development of such medications is significant in managing cardiovascular health.

Upstream product

• 64169-34-2 5-bromophthalide 
• 102126-70-5 5-bromo-3-bromo-3H-isobenzofuran-1-one 
• 75884-70-7 6-bromophthalazin-1(2H)-one 
• 75884-70-7 6-bromophthalazin-1-ol 

Downstream Products

• 918811-38-8 6-bromophthalazin-1-amine 
• 909186-04-5 3-(1-chloro-6-phthalazinyl)-N-cyclopropyl-4-methylbenzamide 
• 909186-42-1 6-bromo-N-cyclohexylphthalazin-1-amine 
• 794591-70-1 6-bromo-N-(4-trifluoromethylphenyl)-1-phthalazinamine 

Relevant articles and documents

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

PROTOZOAN PARASITE GROWTH INHIBITORS

Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be us

PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

PHTHALAZINE DERIVATIVES

The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.

PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2/su

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS

The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.